

December 6, 2010

Maruho Co., Ltd.
Astellas Pharma Inc.

Marketing Collaboration on *Protopic*[®] Ointment for Treatment of Atopic Dermatitis in Japan

Maruho Co., Ltd. (Headquarters: Osaka, President & CEO: Koichi Takagi, hereafter referred to “Maruho”) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, hereafter referred to “Astellas”) announced that the companies have agreed that Astellas will assign detailing/promotional activities for *Protopic*[®] (generic name: tacrolimus hydrate) in Japan to Maruho on April 1, 2011 and thereafter will transfer its distribution right in Japan to Maruho on April 1, 2014.

In contrast, Astellas will maintain the approval of manufacturing and distribution for *Protopic*[®] in Japan.

The companies are committed to promote appropriate use of *Protopic*[®] ointment, and aim to realize the improvement of Quality of Life of more patients suffering from atopic dermatitis, through delivering *Protopic*[®] ointment.

* *Protopic*[®] ointment shall mean *Protopic*[®] ointment 0.1% and *Protopic*[®] ointment 0.03% for pediatric.

#####

Contacts for further or additional information
Maruho Co., Ltd. Public Relations Department Tel:+81-6-6371-8831 Fax:+81-6-6375-1589 http://www.maruho.co.jp/
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com